CTLA-4

CTLA-4 (CD152), Hamster Anti-Mouse

Vudalimab is a fully human bispecific monoclonal antibody targeting both PD-1 and CTLA-4, two key immune checkpoint receptors. By simultaneously blocking these pathways, Vudalimab enhances T-cell activation in the tumor microenvironment and is widely used in research on immune checkpoint blockade, tumor immunology, and combination immunotherapy strategies.

Quavonlimab (MK-1308) represents a novel monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). This therapeutic agent is designed to modulate immune responses by inhibiting CTLA-4, a protein that plays a crucial role in regulating immune checkpoints. Quavonlimab is primarily utilized in research focusing on immune-oncology and the potential enhancement of anti-tumor immunity.

Tuvonralimab (PSB-205; QL1706) is a dual-action immunotherapy agent comprising a combination of Iparomlimab, an anti-PD-1 IgG4 antibody, and Tuvonralimab, an anti-CTLA-4 IgG1 antibody. This formulation is designed to synergistically inhibit both the PD-1 and CTLA-4 immune checkpoints, enhancing antitumor immune responses. Tuvonralimab is utilized primarily in research focused on cancer immunotherapy, aiming to study and potentially enhance the efficacy of checkpoint blockade strategies.

Gotistobart (ONC-392) is a humanized monoclonal antibody targeting CTLA-4, designed to enhance immunotherapeutic efficacy through the selective depletion of regulatory T cells (Tregs) within the tumor microenvironment. This antibody facilitates a targeted approach to modulate the immune system, potentially improving treatment outcomes in cancer immunotherapy.

Porustobart is a monoclonal antibody specifically targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). This antibody is designed for use in research studies to investigate the modulation of immune checkpoints, which are crucial for understanding immune system behavior in cancer and other diseases. Porustobart can be utilized in various experimental settings, including flow cytometry, Western blotting, and immunoprecipitation, making it a valuable tool for researchers focusing on immunology and oncology.

Anti-CTLA-4/CD152 Antibody (BN13) is a chimeric mouse IgG2a, κ antibody designed to target human CTLA-4/CD152. For isotype control, it is recommended to use Mouse IgG2a kappa, Isotype Control, ensuring specificity and consistency in antibody performance.

Bavunalimab is a bispecific monoclonal antibody targeting CTLA-4 and LAG-3, designed for the dual inhibition of these immune checkpoint inhibitors. This humanized antibody promotes T-cell activation, demonstrated in NSG mouse models, making it a valuable tool for investigating immune responses in oncology research. Bavunalimab is specifically developed for studies focusing on the modulation of immune checkpoints in cancer therapy.

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody designed to specifically target and inhibit CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). By antagonizing the inhibitory checkpoints mediated by CTLA-4 signaling, Zalifrelimab enhances immune cell activation, potentially amplifying antitumor immune responses. This antibody is utilized in research focused on immunotherapy and the modulation of immune checkpoints in oncology.

Nurulimab (BCD-145) is a human monoclonal antibody that targets cytotoxic T lymphocyte antigen-4 (CTLA-4). This antibody is specifically designed for use in melanoma research, where it can help investigate the role of CTLA-4 in tumor immunity and potential therapeutic interventions.

Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

The Anti-CTLA-4/CD152 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CTLA-4 (CD152). This antibody comprises a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental controls, the recommended isotype control is Human IgG1 kappa. This antibody is essential for research focusing on immune checkpoint regulation and cancer immunotherapy.

Firastotug is an IgG1κ monoclonal antibody specifically designed to target CTLA-4, a critical immune checkpoint protein associated with cytotoxic T lymphocytes. CTLA-4 plays a pivotal role in regulating immune responses, making it a significant target in the study of autoimmunity and oncology. This antibody is instrumental for researchers focusing on the modulation of immune checkpoints to understand disease mechanisms and develop therapeutic strategies.

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody designed to simultaneously target PD-1 and CTLA-4. By inhibiting these checkpoint pathways, Cadonilimab effectively alleviates immunosuppression and reverses T cell exhaustion specific to tumor environments. This antibody notably reduces Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Cadonilimab is applicable in research focused on metastatic cervical cancer and other malignancies, including gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and non-small cell lung cancer (NSCLC), providing a valuable tool for investigations into immune checkpoint blockade and cancer immunotherapy.

Evalstotug is a human IgG1 κ monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). For accurate experimental control, it is recommended to use Human IgG1 kappa isotype control.

Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART) designed to simultaneously inhibit the activity of PD-1 and CTLA-4 immune checkpoints. By blocking these pathways, Lorigerlimab enhances T-cell mediated immune responses, which are critical in the control and elimination of tumors. This antibody is particularly relevant for studies focused on metastatic castration-resistant prostate cancer (mCRPC), providing a valuable tool for research in immune checkpoint blockade therapies and their role in cancer immunology.

Erfonrilimab (KN-046) is a bifunctional monoclonal antibody designed to simultaneously inhibit both PD-L1 and CTLA-4, two critical immune checkpoint proteins. This dual inhibition mechanism enhances the immune system's ability to recognize and destroy cancer cells, making it a promising therapeutic agent in oncology research. Erfonrilimab is specifically engineered for use in investigating the efficacy of combined checkpoint blockade in various cancer models.

Ipilimumab is a fully human monoclonal antibody of the IgG1κ isotype designed to inhibit the cytotoxic T lymphocyte antigen 4 (CTLA-4) receptor on T cells. This antibody is utilized in research focused on unresectable or metastatic melanoma (MM), serving as a critical tool in investigating the modulation of immune checkpoints in cancer therapy.

Muzastotug is a humanized immunoglobulin G1-kappa monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). It functions as both an immunostimulant and an antineoplastic agent. This antibody is designed to enhance the immune system's response against tumor cells by inhibiting CTLA-4, a protein that downregulates the immune response.

Vilastobart is a human IgG1 κ monoclonal antibody targeting CTLA-4. For accurate experimental control, it is recommended to use Human IgG1 kappa as an isotype control.

Sovipostobart is a human monoclonal antibody of the immunoglobulin G1-kappa class, specifically targeting CTLA-4 with a cleavable prodomain. It functions as both an immunostimulant and an antineoplastic agent. This biologic is designed to modulate the immune system by inhibiting CTLA-4, a protein that downregulates immune responses, thereby enhancing the body's antitumor activity. Sovipostobart is applicable in the study of immune checkpoint blockade therapies and is relevant for research focused on cancer immunotherapy.

Botensilimab (AGEN 1181) is a human monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA-4), serving as both an innate and adaptive immune activator. This biologic is specifically designed for use in cancer research, where it facilitates the study of immune checkpoint blockade and its effects on tumor immunity.

AN02 is a CTLA-4 degrader that demonstrates potent anti-cancer activity in ovarian cancer research. This compound inhibits cell proliferation, clonogenicity, migration, and invasion of ovarian cancer cells while upregulating the expression of antigen-presenting cells (APC). AN02 mediates CTLA-4 degradation through the SMAD4 pathway, significantly reducing tumor growth in small xenograft models and reversing the immune-suppressive tumor environment. Additionally, when used in combination with Ipilimumab, AN02 enhances therapeutic efficacy and inhibits epithelial-mesenchymal transition, making it a valuable tool for studying ovarian cancer.

DZ-2384 is a powerful microtubule-targeting agent known for its role in enhancing rescue frequency and maintaining the microtubule architecture in nonmitotic cells and primary neurons. This compound demonstrates synergistic effects when combined with anti-CTLA-4 immunotherapy, particularly in Taxane-sensitive and resistant xenograft models of triple-negative breast cancer (TNBC). Additionally, DZ-2384 exhibits significant antitumor efficacy in models of adult acute lymphocytic leukemia (ALL), making it a valuable tool for cancer research in these areas.

Davoceticept is a fusion protein consisting of the CD80 (1-107) fragment linked to IGHG1 Fc via a peptidyl linker, targeting CTLA-4 and PD-L1. This variant CD80 vIgD-Fc acts as an immune checkpoint inhibitor, enhancing T cell activation and promoting anti-tumor responses. Its applications include cancer immunotherapy and studying immune modulation in various malignancies, making it a valuable tool for researchers investigating therapeutic strategies in cancer treatment.

KD6001 is a humanized IgG1κ monoclonal antibody that targets CTLA-4, effectively disrupting the interactions between CTLA-4 and its ligands CD80 and CD86, with an IC50 of 16 ng/mL. This antibody promotes the activation of T cells by enhancing the expression of IL-2 and IFNγ in PHA-activated human lymphocytes. KD6001 demonstrates significant antitumor activity, inhibiting tumor growth in various mouse models, including MC38, B16, and Hepa1-6. It is relevant for research applications in cancer, particularly in advanced melanoma, hepatocellular carcinoma, and liver cancer.